{
    "name": "ziv-aflibercept",
    "comment": "Rx",
    "other_names": [
        "Zaltrap"
    ],
    "classes": [
        "Antineoplastics",
        "Tyrosine Kinase Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/zaltrap-ziv-aflibercept-999765",
    "pregnancy": {
        "common": [
            "Based on findings from animal reproduction studies and its mechanism of action, fetal harm may cause when administered to pregnant women",
            "Insufficient data available in pregnant women exposed to ziv-aflibercept to assess the risk",
            "Advise pregnant women of the potential risk to a fetus"
        ],
        "specific": [
            {
                "type": "Animal data ",
                "description": [
                    "Administration of ziv-aflibercept during organogenesis was embryotoxic and teratogenic in rabbits at exposure levels ~0.3 times the human exposure at the 4 mg/kg/dose"
                ]
            },
            {
                "type": "Pregnancy testing",
                "description": [
                    "Verify pregnancy status in females of reproductive potential before initiating ziv-aflibercept"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females or reproductive potential: Use effective contraception during treatment and for 1 month following the last dose"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Advise female and male patients of reproductive potential that treatment may impair reproductive function and fertility"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of drug in human milk, or effects on breastfed infant or on milk production",
            "Owing to the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for 1 month following last dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Increased risk of hemorrhage, including severe and sometimes fatal hemorrhagic events (eg, severe intracranial hemorrhage, pulmonary hemorrhage/hemoptysis); monitor for signs and symptoms of bleeding, and discontinue if needed; do not administer with severe hemorrhage",
                "Gastrointestinal (GI) perforation including fatal GI perforation can occur; monitor for signs and symptoms of bleeding, and discontinue if needed",
                "Grade 3 impaired wound healing was reported; suspend therapy for ≥4 weeks prior to elective surgery; resume therapy ≥4 weeks following major surgery or until surgical wound has healed; for minor surgical procedures (eg, tooth extraction, biopsy, central venous access port placement), resume therapy once surgical wound has healed completely; discontinue in patients with compromised wound healing",
                "Increased risk of fistula formation involving GI and non-GI sites; discontinue if fistula develops",
                "Increased risk of Grade 3-4 hypertension; monitor BP q2weeks or more frequently if indicated; treat with appropriate antihypertensive therapy; temporarily suspend if hypertension uncontrolled, and permanently reduce dose to 2 mg/kg for subsequent cycles once blood pressure normalizes; discontinue with hypertensive encephalopathy or hypertensive crisis",
                "Increased risk of arterial thromboembolic events (eg, TIA, CVA, and angina pectoris); discontinue if thromboembolic event occurs",
                "Increased risk of higher incidence of neutropenic complications (febrile neutropenia and neutropenic infection); monitor CBC with differential count at baseline and prior to initiation of each cycle; delay if neutrophil count ≥1.5 x 10",
                "9",
                "/L",
                "Increased risk of severe diarrhea, especially in patients aged ≥65 years; monitor closely",
                "Increased risk of RPLS (also known as posterior reversible leukoencephalopathy syndrome); confirm RPLS diagnosis with MRI and discontinue if present; RPLS may resolve or improve within days, but some patients have experienced ongoing neurologic sequelae or death",
                "May cause fetal harm based on findings from animal studies and its mechanism of action"
            ],
            "specific": [
                {
                    "type": "Proteinuria",
                    "description": [
                        "Severe proteinuria, nephrotic syndrome, and thrombotic microangiopathy (TMA) occurred more frequently",
                        "Monitor by urine dipstick analysis and urinary protein creatinine ratio (UPCR)",
                        "Obtain 24-hour urine collection in patients with UPCR ≥1; suspend if proteinuria is ≥2 g/24hr, and resume when ≤2 g/24hr; if reoccurs, suspend until ≤2 g/24hr and permanently reduce dose to 2 mg/kg for subsequent cycles; discontinue in patients who develop TMA or nephrotic syndrome"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Leukopenia",
            "percent": "78"
        },
        {
            "name": "Diarrhea",
            "percent": "69"
        },
        {
            "name": "Neutropenia",
            "percent": "67"
        },
        {
            "name": "Proteinuria",
            "percent": "62"
        },
        {
            "name": "AST increased",
            "percent": "62"
        },
        {
            "name": "ALT increased",
            "percent": "50"
        },
        {
            "name": "Stomatitis",
            "percent": "50"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "48"
        },
        {
            "name": "Fatigue",
            "percent": "48"
        },
        {
            "name": "Hypertension",
            "percent": "41"
        },
        {
            "name": "Decreased weight",
            "percent": "32"
        },
        {
            "name": "Decreased appetite",
            "percent": "32"
        },
        {
            "name": "Epistaxis",
            "percent": "28"
        },
        {
            "name": "Abdominal pain",
            "percent": "27"
        },
        {
            "name": "Dysphonia",
            "percent": "25"
        },
        {
            "name": "Increased serum creatinine",
            "percent": "23"
        },
        {
            "name": "Asthenia",
            "percent": "18"
        },
        {
            "name": "Dyspnea",
            "percent": "12"
        },
        {
            "name": "Upper abdominal pain",
            "percent": "11"
        },
        {
            "name": "Neutropenia",
            "percent": "37"
        },
        {
            "name": "Diarrhea",
            "percent": "19"
        },
        {
            "name": "Hypertension",
            "percent": "19"
        },
        {
            "name": "Leukopenia",
            "percent": "16"
        },
        {
            "name": "Stomatitis",
            "percent": "13"
        },
        {
            "name": "Fatigue",
            "percent": "13"
        },
        {
            "name": "Palmar",
            "percent": "11"
        },
        {
            "name": "plantar erythrodysesthesia syndrome",
            "percent": "9"
        },
        {
            "name": "Urinary tract infection",
            "percent": "8"
        },
        {
            "name": "Oropharyngeal pain",
            "percent": "8"
        },
        {
            "name": "Skin hyperpigmentation",
            "percent": "9"
        },
        {
            "name": "Venous thromboembolic events",
            "percent": "6"
        },
        {
            "name": "Hemorrhoids",
            "percent": "5"
        },
        {
            "name": "Rectal hemorrhage",
            "percent": "5"
        },
        {
            "name": "Proctalgia",
            "percent": "5"
        },
        {
            "name": "Pulmonary embolism",
            "percent": "8"
        },
        {
            "name": "Proteinuria",
            "percent": "5"
        },
        {
            "name": "Asthenia",
            "percent": "4"
        },
        {
            "name": "Abdominal pain",
            "percent": "3"
        },
        {
            "name": "Palmar",
            "percent": "3"
        },
        {
            "name": "plantar erythrodysesthesia syndrome",
            "percent": "3"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "3"
        },
        {
            "name": "AST increased",
            "percent": "3"
        },
        {
            "name": "ALT increased",
            "percent": "3"
        },
        {
            "name": "Decreased weight",
            "percent": "1"
        },
        {
            "name": "Decreased appetite",
            "percent": "0.8"
        },
        {
            "name": "Upper abdominal pain",
            "percent": "0.7"
        },
        {
            "name": "Dyspnea",
            "percent": "0.5"
        },
        {
            "name": "Rectal hemorrhage",
            "percent": "0.3"
        },
        {
            "name": "Dysphonia",
            "percent": "0.2"
        },
        {
            "name": "Proctalgia",
            "percent": "0.2"
        },
        {
            "name": "Epistaxis",
            "percent": null
        },
        {
            "name": "Oropharyngeal pain",
            "percent": null
        }
    ]
}